Tuberculosis control in those receiving genetically engineering biologic drugs in Chelyabinsk Region
https://doi.org/10.21292/2075-1230-2019-97-8-5-13
Abstract
Objective: to summarize the experience in screening and monitoring of tuberculosis infection in individuals receiving genetically engineering biological drugs in Chelyabinsk Region for the period from 2014 to 2018.
Subjects and methods. 372 patients were enrolled in the trial, women made 206 (55.4%), men – 166 (44.6%). The average age of patients was 43.85 ± 1.4 years with no differences by gender. Records of 372 patient's histories were analyzed, they contained information on 1,192 visits of patients referred for screening and monitoring of tuberculosis infection while being treated by genetically engineering biologic drugs.
Results. The stages of implementation and the results of screening and monitoring for tuberculosis infection in those receiving therapy with genetically engineering biologic drugs were analyzed at the regional level for 2014-2018. A procedure was developed and introduced to be implemented by a physician for phthisiologic follow-up of patients receiving genetically engineering biologic drugs; indications for computed tomography, IGRA tests were determined, indications for preventive treatment were summarized.
Conclusions. The experience presented in the organization of tuberculosis control those treated with genetic engineering immunobiological therapy allows disseminating a similar model to any region. To work with this “new risk group”, i.e. individuals receiving genetically engineering biologic drugs, it is advisable to concentrate such patients in a head tuberculosis control institution to generate statistical data, as well as to ensure the best results for the detection, diagnosis and treatment of tuberculosis in this category of patients.
About the Authors
V. V. Tinkova
Chelyabinsk Regional Clinical TB Dispensary
Russian Federation
Russian Federation
Valentina V. Tinkova ‒ Deputy Head Doctor for Medical Activities
38, Vorovskogo St.,Chelyabinsk, 454000
M. V. Lekhlyayder
Chelyabinsk Regional Clinical TB Dispensary
Russian Federation
Marina V. Lekhlyayder ‒ Head Physician
Russian Federation
Marina V. Lekhlyayder ‒ Head Physician
38, Vorovskogo St.,Chelyabinsk, 454000
L. E. Grunina
Chelyabinsk Regional Clinical TB Dispensary
Russian Federation
Russian Federation
Lyudmila E. Grunina ‒ Phthisiologist of Dispensary Phthisiology Department no. 1
38, Vorovskogo St.,Chelyabinsk, 454000
K. V. Savelieva
Chelyabinsk Regional Clinical TB Dispensary
Russian Federation
Ksenia V. Savelieva ‒ Phthisiologist of Dispensary Phthisiology Department no. 1
Russian Federation
Ksenia V. Savelieva ‒ Phthisiologist of Dispensary Phthisiology Department no. 1
38, Vorovskogo St.,Chelyabinsk, 454000
References
1. Belov B.S. Therapy with genetically engineering biologic drugs and infections in patients with rheumatoid arthritis: relevance and prospects. Nauchno-Prakticheskaya Revmatologiya, 2014, vol. 52, no. 3, pp. 322-330. (In Russ.)
2. Belov B.S., Naumtseva M.S., Tarasova G.M., Bukhanova D.V. Biological therapy and infections in those with rheumatoid arthritis. Modern aspects. Meditsinsky Soviet, 2016, no. 11, pp. 106-118. (In Russ.)
3. Borisov S.E., Lukina G.V. Rekomendatsii po skriningu i monitoringu tuberkuleznoy infektsii u bolnykh, poluchayuschikh genno-inzhenernye biologicheskie preparaty. [Recommendations for screening and monitoring of tuberculous infection in rheumatologic patients, treated by genetically engineered biological agents]. Available: www.rheumatolog/files/natrec21/pdf.
4. Borisov S.E., Lukina G.V., Slogotskaya L.V., Guntupova L.D., Kulikovskaya N.V. Screening and monitoring of tuberculous infection in rheumatologic patients, treated by genetically engineered biological agents. Tuberculosis and Lung Diseases, 2011, no. 6, pp. 42-50. (In Russ.)
5. Kochetkov Ya.A. Skrining i monitoring tuberkuleznoy infektsii u revmatologicheskikh bolnykh pri lechenii ingibitorami faktora nekroza opukholi. Avtoref. diss. kand. med. nauk. [Screening and monitoring of tuberculous infection in patients with rheumatologic disorders when treated with anti-tumor necrosis factor agent. Sinopsis of Cand. Diss.]. Moscow, 2012, 23 p.
6. Moiseeva N.N., Odinets V.S. Experience of using Diaskintest in mass screening for tuberculosis. Tuberculosis and Lung Diseases, 2015, no. 7, pp. 92-93. (In Russ.)
7. Pozdeeva N.V., Kokovikhina I.А., Аnikhovskaya O.N. Diaskintest for diagnostics of tuberculosis in adults. Tuberculosis and Lung Diseases, 2015, no. 6, pp. 115. (In Russ.)
8. Skrining i monitoring tuberkuleznoy infektsii u revmatologicheskikh bolnykh, poluchayuschikh genno-inzhenernye biologicheskie preparaty. Metodicheskie rekomendatsii. [Screening and monitoring of tuberculous infection in rheumatologic patients, treated by genetically engineered biological agents. Guidelines]. Аssotsiatsiya Revmatologov Rossii Publ., Developed by: Lukina G.V., Borisov S.E., Sigedin Ya.А., Belov B.S., Smirnov А.V. 2015, pp. 13.
9. Slogotskaya L.V., Bogorodskaya E.M. Comparative description of tuberculin tests for tuberculous infection detection. Mass screening opportunities. Tuberculosis and Lung Diseases, 2016, no. 5, pp. 5-16. (In Russ.)
10. Teschenkov А.V., Shumilov P.V., Myakishev T.V., Аvdeeva T.G. The development and course of latent tuberculosis infection in children with rheumatoid arthritis. Vestnik Smolenskoy Gosudarstvennoy Meditsinskoy Akademii, 2016, no. 15 (4), pp. 64-71. (In Russ.)
11. Chichasova N.V., Nasonov E.L. The safety of using genetically engineering biologic drugs for treatment of rheumatoid arthritis. Sovr. Revmatologiya, 2010, no. 10 (1), pp. 46-58. (In Russ.)
12. Bombardiner C., Hazlewood G.S., Akhavan P. et al. Canadian Rheumatology Association recommendations for the pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs: part II safety. J. Rheumatolol., 2012, vol. 39, no. 8, pp. 1583-1602.
13. Cantini F., Nannini C., Niccoli L. et al. Risk of tuberculosis reactivation in patients with Rheamatoid Arthritis, Ankylosing Spondilitis and Psoriatic Arthritis receving non-anti-TNF-targeted biologics. Mediators Infarm., 2017, Published online 2017 Jun 1 doi: 10.1155/2017/8909834.
14. Cantini F., Nannini C., Niccoli L. et al. SAFEBIO (Italian multidisciplinary task force for screening of tuberculosis before and during biologic therapy). Autoimmun. Rev., 2015, vol. 14, no. 6, pp. 503-509.
15. Dobler C.C. Biologic agents and tuberculosis: risk estimates and screening strategies. Int. J. Rheum. Dis., 2015, vol. 18, no. 3, pp. 264-267.
16. Duarte R., Campainha S., Cotter J. et al. Portuguese Society of Pulmonology; Portuguese Society of Gastroenterology; Portuguese Society of Dermatology and Venereology; Portuguese Society of Rheumatology. Position paper on tuberculosis screening in patients with immune mediated inflammatory diseases candidates for biological therapy. Acta Reumatol Port, 2012, vol. 37, no. 3, pp. 253-259.
17. Goletti D., Petrone L., Ippolito Gl. et al. Preventive therapy for tuberculosis in rheumatological patients undergoing therapy with biological drugs. Expert Review of Anti-infective Therapy, 2018, vol. 16, no. 6, pp. 501-512.
18. Hasan T., Au E., Chen S. et al. Screening and prevention for latent tuberculosis in immunosupressed patients at risk for tuberculosis: a systematic review of clinical practice guidelines. BMJ Open, 2018, vol. 8, no. 9, pp. e022445.
19. Hernandez C., Cetner A.S., Jordan J.E. et al. Tuberculosis in the age of biologic therapy. J. Am. Acad. Dermatol., 2008, vol. 59, no. 3, pp. 363-380.
20. Naderi H.R., Sheybani F., Rezaei Pajand S. How should we manage latent tuberculosis infection in patients receiving anti-TNF-α drugs: literature review. Iran. Red Crescent Med. J., 2016, vol. 18, no. 12, pp. 27756.
21. Ramos S., Nogueira A., Dias A. et al. Tuberculosis screening in patients receiving biological therapy. Acta. Reumatol. Port., 2015, vol. 40, no. 3, pp. 234-240.
22. Singh J.A., Saag K.G., Bridges S.L.Jr. et al. 2015 American college of rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol., vol. 68, no. 1, pp. 1-26.
23. Viladrich I., Dauden Tello E., Solano-Lopez G. et al. Consensus document on prevention and treatment of tuberculosis in patients for biological treatment. Consensus document on prevention and treatment of tuberculosis in patients for biological treatment. Archivos de Bronconeumologia, 2015, vol. 14, Jul., no. 52 (1), pp. 36-45.
Review
For citations:
Tinkova V.V., Lekhlyayder M.V., Grunina L.E., Savelieva K.V. Tuberculosis control in those receiving genetically engineering biologic drugs in Chelyabinsk Region. Tuberculosis and Lung Diseases. 2019;97(8):5-13. (In Russ.) https://doi.org/10.21292/2075-1230-2019-97-8-5-13
Views:
1291
Email this article 